Through B cell phenotype characterization, we could show that MS patients exhibited a significantly higher naïve B cell population and consequently lower memory (CD27+) subsets than the control group before and after SARS-CoV-2 vaccination. This evidence concerns the gene CD27 and myeloid sarcoma.